SWP
CATX icon

Stratos Wealth Partners’s Perspective Therapeutics CATX Stock Holding History

Stratos Wealth Partners’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,000
Closed -$6K – 1262
2021
Q3 		$6K Hold
1,000
– – ﹤0.01% 1181
2021
Q2 		$8K Hold
1,000
– – ﹤0.01% 1186
2021
Q1 		$11K Buy
+1,000
New +$15.1K ﹤0.01% 1113

Other funds holding CATX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
HPWM
Highland Private Wealth Management Bellevue, Washington $620M AUM 18.88% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TMWM
Taylor & Morgan Wealth Management Flint, Michigan $203M AUM 24.74% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Stratos Wealth Partners's CATX Position: Q4 2021 in Review

Stratos Wealth Partners sold out of Perspective Therapeutics (CATX) in Q4 2021, closing a stake of 1,000 shares — an estimated $6K sold.

Stratos Wealth Partners first reported a position in CATX in Q1 2021 and held it in 3 quarters. The position peaked at $11K in Q1 2021. 45 funds tracked by Wall St. Rank hold CATX as of Q4 2021.

  • Stratos Wealth Partners reported no remaining Perspective Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Stratos Wealth Partners sold 1,000 Perspective Therapeutics shares in Q4 2021, an estimated $6K.
  • Stratos Wealth Partners first reported a position in Perspective Therapeutics in Q1 2021 and held it in 3 quarters.
  • Stratos Wealth Partners's Perspective Therapeutics position peaked at $11K in Q1 2021.
  • 45 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q4 2021.

Based on Stratos Wealth Partners's 13F filing for Q4 2021, filed 14 Jan 2022.